We demonstrated that SLC-0111, a novel CAIX inhibitor, is able to synergise with Dacarbazine and its derivative Temozolomide, Doxorubicin and 5-Fluorouralcil in the treatment of melanoma, breast, and colorectal cancer, respectively, which, as reported in our previous paper10, express a significant level of mRNA and protein of CAIX also in normoxia. This evidence concerns the gene CA9 and colorectal cancer.